# US 2025/0145963 A1 · Improved Differentiation Method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145963 A1
- Document ID: US20250145963A1
- Status: Published application
- Kind: A1
- Application number: 18/918,172
- Filed: 2024-10-17
- Published: 2025-05-08
- Earliest claimed: 2016-06-20
- Assignees: Koninklijke Nederlandse Akademie van Wetenschappen
- Applicants: Koninklijke Nederlandse Akademie Van Wetenschappen
- Inventors: Johannes Carolus Clevers; Joep Beumer
- Web page: https://patentgrep.com/patent/US20250145963A1

## CPC

- C12N 5/0679: {Cells of the gastro-intestinal tract}
- C12N 5/068: {Stem cells; Progenitors}
- A61K 35/38: Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0062: {General methods for three-dimensional culture}
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/42: Notch; Delta; Jagged; Serrate
- C12N 2503/02: Drug screening
- C12N 2513/00: 3D culture
- G01N 2500/10: involving cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to methods and media for differentiating cells, for example for obtaining enteroendocrine cells, and to uses of the cells and organoids obtained by said methods. The invention also relates to methods for modulating hormone expression in enteroendocrine cells and medical uses relating to such methods.

## Claims

### Claim 1

A method for differentiating progenitor cells, wherein said method comprises:
culturing the cells in a differentiation medium comprising a basal medium and further comprising one or more EGFR pathway inhibitors, a Notch inhibitor and one or more Wnt inhibitors.

### Claim 2 (depends on 1)

The method of claim 1, wherein:
a. the one or more EGFR pathway inhibitors:
i. is selected from: (1) an EGFR inhibitor, (2) an EGFR and ErbB2 inhibitor, (3) an inhibitor of the RAS-RAF-MAPK pathway, (4) an inhibitor of the PI3K/AKT pathway and (5) an inhibitor of the JAK/STAT pathway; and/or
ii. comprises:
A. an EGFR inhibitor, such as Gefitinib:
B. an EGFR and ErbB-2 inhibitor, such as Afatinib; and/or
C. an inhibitor of the RAS-RAF-MAPK pathway, e.g. a MEK inhibitor, such as PD0325901, and/or an ERK inhibitor, such as SCH772984;
b. the Notch inhibitor is a gamma-secretase inhibitor, optionally DAPT or dibenzazepine (DBZ) or benzodiazepine (BZ) or LY-411575; and/or
c. the one or more Wnt inhibitors is selected from: (1) an inhibitor of Wnt secretion, (2) a competitive or non-competitive inhibitor of the interaction between Wnt or Rspondin and the Wnt receptor complex, (3) an inhibitor that promotes the degradation of components of the Wnt receptor complex, (4) an inhibitor of Dishevelled family proteins, (5) an activator that promotes destruction complex activity, (6) an inhibitor of the deoligomerisation of the destruction complex and/or (7) an inhibitor of β-catenin target gene expression, optionally wherein the one or more Wnt inhibitors comprise an inhibitor of Wnt secretion, e.g. a Porc inhibitor selected from IWP 2, LGK974 and IWP 1.

### Claim at position 3

-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the differentiation medium further comprises:
a. one or more components selected from the group consisting of: a p38 inhibitor, a TGF-beta inhibitor, gastrin, a glucocorticoid, a receptor tyrosine kinase ligand, a BMP pathway activator, a cAMP pathway activator, a Hedgehog activator, a Hedgehog inhibitor, a modulator of mTOR signalling, B27 and N2;
b. one or more components selected from the group consisting of: a p38 inhibitor, a TGF-beta inhibitor, gastrin, a glucocorticoid, a receptor tyrosine kinase ligand, a BMP inhibitor, a cAMP pathway activator, a Hedgehog activator, a Hedgehog inhibitor, a modulator of mTOR signalling, B27 and N2;
c. a BMP activator, such as BMP7, BMP4 or BMP2; or
d. a BMP inhibitor, such as noggin, sclerostin, chordin, CTGF, follistatin, gremlin, tsg, sog, LDN193189 or dorsomorphin,
optionally, wherein the differentiation medium comprises less than 1 mM EGF.

### Claim 11

A differentiation medium comprising a basal medium and further comprising one or more EGFR pathway inhibitors, a Notch inhibitor and one or more Wnt inhibitors.

### Claim 12 (depends on 11)

A method for differentiating intestinal progenitor cells to obtain a population of intestinal cells enriched in enteroendocrine cells, wherein said method comprises:
culturing the intestinal progenitor cells in a differentiation medium according to claim 11.

### Claim 13 (depends on 11)

A method for culturing epithelial stem cells, wherein said method comprises:
culturing the epithelial stem cells in the presence of an expansion medium for epithelial stem cells to obtain expanded epithelial stem cells; and subsequently
culturing the one or more expanded cells in a differentiation medium according to claim 11.

### Claim 14 (depends on 1)

The method of claim 1, wherein:
a. the cells are cultured in contact with an extracellular matrix;
b. the method further comprises obtaining and/or isolating a differentiated cell population or a differentiated organoid;
c. the progenitor cells are epithelial cells, for example, from the intestine, stomach, pancreas, liver, prostate, lung, breast, ovary, salivary gland, hair follicle, skin, oesophagus, bladder, ear or thyroid;
d. the progenitor cells are from the intestine, stomach, pancreas or lung; and/or
e. the progenitor cells are mammalian progenitor cells, for example, human progenitor cells.

### Claim at position 9

-18. (canceled)

### Claim 19 (depends on 11)

A method for culturing intestine epithelial stem cells, preferably to obtain a differentiated intestine organoid, and wherein said method comprises:
culturing one or more intestine epithelial stem cells in contact with an extracellular matrix in the presence of an expansion medium; preferably wherein the expansion medium comprises a basal medium, and further comprises: a receptor tyrosine kinase ligand, a BMP inhibitor and a Wnt agonist and, optionally, valproic acid and a GSK-3 inhibitor (e.g. CHIR99021); and subsequently
culturing the one or more expanded intestine epithelial stem cells in contact with an extracellular matrix in the presence of a differentiation medium according to claim 11.

### Claim 20 (depends on 1)

An organoid obtainable or obtained by a method of claim 1.

### Claim 21 (depends on 20)

The organoid of claim 20, wherein the organoid is derived from the liver, pancreas, intestine, stomach, prostate, lung, breast, ovarian, salivary gland, hair follicle, skin, oesophagus, bladder, ear or thyroid, preferably from the intestine, stomach, pancreas or lung.

### Claim 22 (depends on 20)

An organoid according to claim 20, wherein the organoid is derived from:
a. a human, and in which at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 99% of the cells express enteroendocrine cell markers; or
b. a mouse, and in which at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 99% of the cells express enteroendocrine cell markers;
optionally wherein the enteroendocrine cell markers are selected from Chga, Chgb, Tac1, Tph1, Gip, Fabp5, Ghr1, Pyy, Nts, Neurod1, Sst, Sct, cholecystokinin, glucagon and/or pro glucagon.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 20)

A composition comprising an organoid according to claim 20, and a differentiation medium comprising a basal medium and further comprising one or more EGFR pathway inhibitors, a Notch inhibitor and one or more Wnt inhibitors.

### Claim 26

(canceled)

### Claim 27 (depends on 20)

A method of treating a disorder, condition or disease comprising transplanting the organoid according to claim 20, or a cell derived from said organoid into a patient.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 20)

A method for screening for a therapeutic or prophylactic pharmaceutical drug or cosmetic, wherein the method comprises:
contacting a differentiated organoid according to claim 20 with a candidate molecule (or a library of candidate molecules),
evaluating said organoid for any effects (e.g. any change in the cell, such as a reduction in or loss of proliferation, a morphological change and/or cell death) or a change in organoid (e.g. the organoid size or motility);
identifying the candidate molecule that causes said effects as a potential drug or cosmetic; and optionally
preparing said candidate molecule as pharmaceutical or cosmetic.

### Claim at position 22

-35. (canceled)

### Claim 36 (depends on 11)

A method of obtaining a population of cells enriched in EECs, wherein the method comprises culturing a population of cells in a differentiation medium according to claim 11.

### Claim 37 (depends on 36)

The method of claim 36, wherein:
a. the population of cells is enriched in GLP1-secreting EECs, and wherein the differentiation medium comprises a BMP inhibitor; or
b. the population of cells is enriched in secretin-secreting EECs, wherein the differentiation medium comprises a BMP pathway activator.

### Claim 38

(canceled)

### Claim 39

A method of:
a. treating or preventing diabetes mellitus or an associated disease or disorder; or
b. treating hyperchlorhydria or obesity,
wherein the method comprises administering a therapeutically effective amount of a BMP inhibitor to a subject in need thereof.

### Claim 40

(canceled)
